ImmunityBio (IBRX) Accumulated Expenses (2014 - 2026)

ImmunityBio (IBRX) has 13 years of Accumulated Expenses data on file, last reported at $48.2 million in Q1 2026.

• Quarterly Accumulated Expenses rose 72.84% year-over-year to $48.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $48.2 million (up 72.84% YoY) and the FY2025 annual result came in at $46.8 million, up 15.42% from the prior year.
• Accumulated Expenses climbed to $48.2 million in Q1 2026 per IBRX's latest filing, from $46.8 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $64.9 million in Q3 2023 and bottomed at $27.9 million in Q1 2025.
• The 5-year median for Accumulated Expenses is $43.6 million (2025), against an average of $46.0 million.
• The widest annual swing landed in 2024, when Accumulated Expenses sank 43.3%; it then surged 72.84% in 2026.
• Tracing IBRX's Accumulated Expenses over 5 years: stood at $41.8 million in 2022, then climbed by 2.11% to $42.7 million in 2023, then declined by 4.98% to $40.6 million in 2024, then advanced by 15.42% to $46.8 million in 2025, then gained by 2.92% to $48.2 million in 2026.
• Per Business Quant, the three latest IBRX Accumulated Expenses figures stand at $48.2 million (Q1 2026), $46.8 million (Q4 2025), and $43.6 million (Q3 2025).

Peer Comparison